Infectious upper respiratory / ophthalmic disease in kittens: doxycycline + famciclovir vs doxycycline alone — POSSIBLE

In kittens with infectious ophthalmic/respiratory disease, does adding famciclovir to doxycycline speed clinical resolution and reduce corneal complications vs doxycycline + placebo?

Shelf #146 · gate-verified and displayed under the developer's blinded-trial rule

POSSIBLE: Adding a full course of famciclovir to doxycycline probably helps kittens whose infectious upper respiratory / ophthalmic disease is still mild, and probably reduces corneal disease. In a prospective, randomized, masked, placebo-controlled trial in 373 kittens, mildly affected kittens on doxycycline + famciclovir reached clinical recovery (P = 0.049) and clinical resolution (P = 0.030) faster than kittens on doxycycline alone, reaching predicted 75% clinical resolution 4–5 days earlier; significantly fewer famciclovir kittens developed corneal disease (P = 0.016), and all five kittens removed from the study for worsening were on doxycycline alone. In severe disease the advantage was not shown. A single dose is a different question: in shelter cats, one dose of famciclovir at intake did nothing (Litster 2015) — the benefit carded here belongs to the twice-daily course started early, not to famciclovir in any form. Drafted Nov 10, 2026 (VetMed build, topic #146); all figures from abstracts fetched and verified at drafting.

Vernau 2024: in 373 kittens, adding famciclovir to doxycycline sped resolution in mild disease and cut corneal disease (P = 0.016)

Prospective, randomized, masked, placebo-controlled trial (record's own title wording; abstract specifies randomized, triple-masked, placebo-controlled)

Who: Cats: 373 kittens with ocular manifestations of infectious upper respiratory disease, stratified by age (1 to <4, 4 to <8, or 8–12 weeks) and disease severity (mild, total disease score 1–11; severe, 12–23), in a prospective, randomized, triple-masked, placebo-controlled trial — approximately 5 mg/kg doxycycline with either placebo (group D) or approximately 90 mg/kg famciclovir (group DF) orally every 12 hours for 21 days, with daily caregiver scoring and veterinary ophthalmic examinations on days 1 and 21.

Result: For kittens with mild disease, group D was slower than group DF to achieve clinical recovery (P = 0.049) and clinical resolution (P = 0.030), but not ophthalmic recovery (P = 0.064) or ophthalmic resolution (P = 0.089). Kittens with mild disease receiving famciclovir achieved predicted 75% clinical resolution 4–5 days earlier than kittens with mild disease receiving doxycycline alone, and than kittens with severe disease regardless of treatment group. Significantly fewer kittens in group DF developed corneal disease than in group D (P = 0.016). All five kittens whose clinical signs worsened sufficiently to be removed from the study were in group D. The authors conclude early famciclovir in mild disease may be preferable to delaying it until disease becomes severe.

Watch out: The time-to-resolution benefit was shown in mild disease, not severe; ophthalmic (eye-only) recovery and resolution differences in mild disease did not reach significance (P = 0.064 and 0.089). The record is not indexed with a Randomized Controlled Trial publication type; the randomised, triple-masked, placebo-controlled design is established by the title and abstract's own wording.

Vernau KM, Kim S, Thomasy SM et al. Doxycycline with or without famciclovir for infectious ophthalmic and respiratory disease: a prospective, randomized, masked, placebo-controlled trial in 373 kittens. J Feline Med Surg. 2024;26(11):1098612X241278413. PMID: 39485362. Registry ID: none in the record. MeSH: Animals · Cat Diseases · Cats · Respiratory Tract Infections · Doxycycline · Famciclovir · Anti-Bacterial Agents · Prospective Studies · Antiviral Agents · Male · Female · Drug Therapy, Combination · Treatment Outcome

Litster 2015: a single dose of famciclovir at shelter intake did not help — ocular/nasal signs worsened over 7 days in both groups

Randomized, masked, placebo controlled study (record's own wording, two parts: pilot and clinical trial); indexed as Randomized Controlled Trial

Who: Cats: cats entering a shelter, in a two-part randomized, masked, placebo controlled study — a single oral dose of 125 mg famciclovir (n = 43) or placebo (n = 43) in the pilot study, or 500 mg famciclovir (n = 41) or placebo (n = 40) in the clinical trial, given on entering the shelter; feline herpesvirus type 1 (FHV-1) PCR testing, bodyweight, food intake and respiratory-disease signs were recorded before and 7 days after treatment. FHV-1 DNA was detected in 40% of cats in both parts at study entry.

Result: A single dose of famciclovir (125 or 500 mg) administered at shelter intake was not efficacious. In the pilot study, ocular and nasal discharge scores increased from days 1 to 7 in both famciclovir and placebo cats, sneezing scores increased and bodyweight decreased in famciclovir-treated cats, and the proportion of cats in which FHV-1 DNA was detected increased over time in all cats. In the clinical trial, food intake and median clinical scores for nasal discharge and sneezing increased from days 1 to 7 in both groups, demeanor scores worsened in famciclovir-treated cats, and the proportion of cats shedding FHV-1 DNA was greater on day 7 than day 1 in cats receiving 500 mg famciclovir.

Watch out: This is a different regimen and population from Vernau 2024 — one single dose, in shelter cats (not a 21-day course in young kittens) — so its null result limits single-dose use; it does not contradict the kitten trial's course-of-treatment finding. Forty percent of cats were already shedding FHV-1 at intake.

Litster AL, Lohr BR, Bukowy RA, Thomasy SM, Maggs DJ. Clinical and antiviral effect of a single oral dose of famciclovir administered to cats at intake to a shelter. Vet J. 2015;203(2):199-204. PMID: 25542064. Registry ID: none in the record. MeSH: 2-Aminopurine · Animals · Antiviral Agents · Cat Diseases · Cats · Dose-Response Relationship, Drug · Famciclovir · Female · Herpesviridae Infections · Male · Pilot Projects · Real-Time Polymerase Chain Reaction · Respiratory Tract Infections · Varicellovirus · Viral Load · Virus Shedding

Synthesis: course famciclovir early in mild kitten disease helps; a single dose at shelter intake does not

Synthesis

Who: Synthesis of the cards above: Vernau 2024 (prospective, randomized, masked, placebo-controlled trial, 373 kittens, 21-day twice-daily famciclovir course added to doxycycline) and Litster 2015 (randomized, masked, placebo controlled study, 167 shelter cats, single famciclovir dose).

Result: Read together, the two trials draw a clean line: famciclovir's benefit depends on giving a real course, early, while disease is mild — faster clinical resolution by about 4–5 days to the 75% mark and less corneal disease in 373 kittens — whereas a one-off dose in already-shedding shelter cats changed nothing. The stamp is POSSIBLE rather than higher because the kitten trial's clearest wins sit in the mild-disease stratum, its eye-specific endpoints in that stratum missed significance, and severe-disease kittens showed no demonstrated advantage.

Watch out: Neither trial cards a mortality or survival claim, and neither supports delaying famciclovir until disease is severe — on the kitten record, that is exactly when the demonstrated benefit disappears.

Synthesis of Vernau KM et al. PMID: 39485362; Litster AL et al. PMID: 25542064. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.